![download promethium for serum download promethium for serum](https://igg-games.com/wp-content/uploads/2017/08/Promethium-Free-Download.jpg)
![download promethium for serum download promethium for serum](https://www.antidoteaudio.com/wp-content/uploads/2019/05/Massive-Skin-For-Xfer-Serum-300x242.jpg)
Serum is one of the world’s biggest producers of the Covishield vaccine. Serum, Biocon to work on HIV, dengue meds “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics,” said Kiran Mazumdar-Shaw, executive chairperson of Biocon & Biocon Biologics. In return, Biocon’s biologics business arm will get access to 100 million doses of vaccines annually for 15 years, mainly from Serum’s upcoming facility in Pune, with commercialisation rights of the SILS vaccine portfolio (including Covid-19 vaccines) for global markets. That is 25% higher than what Goldman Sachs valued the company at when it invested $150 million last year. It then took just 11 days to reach 80 crore from 70 crore.Īccording to official sources, over 22 per cent of India's adult population have received both doses of COVID-19 vaccine and nearly 65 per cent have got at least one dose.BENGALURU: Serum Institute Life Sciences (SILS), a unit of Serum Institute of India, will buy a 15% stake in Biocon Biologics at a post-money valuation of about $5 billion, the two companies said. It took 19 more days to go past the 60-crore mark and took only 13 days to reach 70 crore from 60 crore on September 7. The country took 24 days to reach 40 crore from 30 crore doses and then 20 more days to cross the 50-crore vaccination mark on August 6, it said. India took 85 days to touch the 10-crore vaccination mark, 45 more days to cross the 20-crore mark and 29 more days to reach the 30-crore mark, according to the ministry. The daily COVID-19 vaccination in the country was over 1 crore on September 6, August 31 and August 27. India on September 17 administered a record number of over 2.50 crore COVID-19 vaccine doses on the occasion of Prime Minister Narendra Modi's 71st birthday. Of all the vaccine doses administered, around 88.45 per cent are Covishield, around 11.44 per cent are Bharat Biotech's Covaxin and less than one per cent are Sputnik V. The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive has crossed 82 crore. Talking about the expected production and supply trends in the coming months, the minister said the government will receive over 30 crore doses of COVID-19 vaccines in October and over 100 crore doses in the coming quarter from October-December. Union Health Minister Mansukh Mandaviya on Monday announced that India will resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 under the 'Vaccine Maitri' programme and to meet its commitment to the COVAX global pool, but vaccinating its own citizens remains the topmost priority of the government. We are working relentlessly to fulfill our prime minister's dream for successful completion of world's largest vaccination drive so that our country overcomes COVID-19 pandemic," the communication stated. "At this juncture, I can assure you that by December 31, 2021, we will complete supply of 66 crore doses of Covishield against the recent order and will touch supplies of more than 130 crore doses of Covishield in the year 2021. Singh futher assured that by December 31, keeping with the timeline, the firm will complete the recent supply order of 66 crore doses. "All this has become possible under the dynamic leadership and kind direction of our Prime Minister Narendra Modi Ji, continuous support from team Ministry of Health and GoI, visionary leadership of our CEO, Dr Adar C Poonawalla, along with untiring efforts of Team SIIPL," a source quoted Singh as having communicated. "Starting from January 2021, we have supplied 66.33 crore doses of Covishield to MoHFW, Government of India in addition to supply of more than 7.77 crore doses to state governments and private hospitals till 19th September 2021 evening. The Pune-based pharmaceutical company has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month.